Cognitive impairments are a core feature in schizophrenia patients and are also observed in first-degree relatives of the schizophrenia patients. However, substantial variability in the impairments exists within and among schizophrenia patients, first-degree relatives and healthy controls. A cluster-analytic approach can group individuals based on profiles of traits and create more homogeneous groupings than predefined categories. Methods: Here, we investigated differences in the Brief Assessment of Cognition in Schizophrenia (BACS) neuropsychological battery (six subscales) among 81 schizophrenia patients, 20 unaffected first-degree relatives and 25 healthy controls. To identify three homogeneous and meaningful cognitive groups regardless of categorical diagnoses (schizophrenia patients, first-degree relatives and healthy controls), cognitive clustering was performed using a k-means clustering analysis approach, and differences in the BACS subscales (verbal memory, digit sequencing, token motor, verbal fluency, symbol coding and Tower of London) among the cognitive cluster groups were investigated. Finally, the effects of diagnosis and cognition on brain volumes were examined. Results: As expected, there were significant differences in the five BACS subscales among the diagnostic groups (verbal memory, F2,123=20.6, P=1.90 × 10-8; digit sequencing, F2,123=8.0, P=5.65 × 10-4; token motor, F2,123=16.0, P=6.92 × 10-7; verbal fluency, F2,123=14.8, P=1.79 × 10-6 and symbol coding, F2,123=28.8, P=5.64 × 10-11). The cluster-analytic approach generated three meaningful subgroups: (i) neuropsychologically normal (Cluster 1, N=36), (ii) intermediate impaired (Cluster 2, N=60) and (iii) widespread impaired (Cluster 3, N=30). The cognitive subgroups were mainly affected by the clinical diagnosis (χ2=46.7, P=5.33 × 10-10), and significant differences in all BACS subscales among clusters were found (verbal memory, F2,123=64.1, P=8.49 × 10-20; digit sequencing, F2,123=35.7, P=5.89 × 10-13; token motor, F2,123=71.7, P=2.29 × 10-21; verbal fluency, F2,123=84.2, P=9.05 × 10-24; symbol coding, F2,123=115.6, P=5.70 × 10-29 and Tower of London, F2,123=6.9, P=1.43 × 10-3). The effects of the diagnosis (SCZ<FR<HC) and cognitive clusters (Clusters 3<2<1) on brain volumes overlapped in the frontal, temporal and limbic regions. Frontal and temporal volumes were mainly affected by the diagnosis, whereas the anterior cingulate cortex volumes were affected by the additive effects of diagnosis and cognition (FWEcorrected P<0.05, x, y, z=1.5, 40.5, 19.5, T=5.49). Discussion: We investigated the cognitive heterogeneity and cognitive continuum among schizophrenia patients, first-degree relatives and healthy controls. The cognitive clustering approach without using clinical diagnoses successfully produced more homogeneous cognitive clusters: a neuropsychologically normal, an intermediately impaired and a globally impaired cognitive cluster. Clinical diagnoses (healthy controls, first-degree relatives and schizophrenia patients) were not evenly distributed into the three clusters; i.e., these clusters were mainly affected by clinical diagnoses. Both diagnoses and cognitive clusters were associated with decreased anterior cingulate cortex volumes. Our findings demonstrate a cognitive continuum among schizophrenia patients, first-degree relatives and healthy controls and support the hypothesis that cognitive impairments and the related anterior cingulate cortex volumes would be useful intermediate phenotypes in the pathophysiology of schizophrenia.
F74. CLINICAL SYMPTOMS AND NOT
recommends that drugs that exert a pro-cognitive effect should be accompanied by measurable improvements in 'real-world' functioning.
Patients with schizophrenia typically exhibit substantial impairments across a wide range of cognitive domains, representing an important target for therapeutic intervention. This has led to the development of several instruments specifically for use in this population that seek to capture the subjective experience and impact of cognitive dysfunction on daily living for use as co-primary endpoints in clinical trials. However, it remains unclear to what extent these accurately reflect objective cognitive performance.
Methods:
We conducted a secondary analysis of data from 413 patients with schizophrenia who participated in a multi-national randomized, double-blind, placebo-controlled trial. During the trial, participants completed two different neurocognitive test batteries, the Cambridge Neuropsychological Test Automated Battery (CANTAB) and the MATRICS Consensus Cognitive Battery (MCCB). They also completed two measures of subjective cognitive performance, the Schizophrenia Cognition Rating Scale (SCoRS) and the Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS). The severity of patient's symptoms was also assessed at each time point using the Positive and Negative Syndrome Scale (PANSS). All assessments were conducted at baseline and at a 12-week follow-up assessment (end of treatment). We examined the associations between these variables using correlational and multivariable linear regression analyses. Results: Scores on each of the subjective measures of cognition were weakly correlated in the expected direction with objective measures of cognitive performance across both the CANTAB and MCCB tasks. Scores on each of the subjective cognition measures were more strongly associated with severity of symptoms as assessed using the PANSS. Multivariable regression analyses suggested that clinical symptoms accounted for significantly greater variance in subjective cognition scores than either objective cognitive performance or demographic factors. Discussion: Subjective appraisals of cognition are poor predictors of objective cognitive performance in patients with schizophrenia. The burden reported by patients on these instruments appears to be more closely associated with the severity of their clinical symptoms. This has important implications for the use of these measures as co-primary endpoints in clinical trials assessing pro-cognitive drug effects. Background: Adherence to antipsychotic treatment is essential in treating schizophrenia symptoms and in preventing costly relapse. This study aimed to compare medication adherence and discontinuation in patients with schizophrenia treated with aripiprazole once-monthly long-acting injectable antipsychotic (LAI; AOM 400) to those who changed to a different oral antipsychotic. Methods: This retrospective cohort analysis used the Truven Health Analytics MarketScan® Medicaid, commercial, and supplemental Medicare claims databases. In patients ≥18 years old with schizophrenia, two mutually exclusive cohorts were created: the AOM 400 cohort, patients who initiated AOM 400 between 01/01/2013-06/30/2015 (the ID period); and the oral cohort, patients who changed to a different oral antipsychotic during the ID period. AOM 400 or new oral therapy initiation was the index date. Patients were followed for ≥1 year. Primary outcome measures were adherence (proportion of days covered [PDC]) during 1-year postindex and index medication discontinuation (gap ≥60 days) during entire follow-up. Cox regression and linear regression models were used to estimate risk of discontinuation and PDC, respectively, adjusting for demographic and clinical characteristics, insurance type, baseline medication, and baseline ED visits or hospitalizations. Results: The study sample consisted of 408 (10.8%) AOM 400 patients and 3,361 (89.2%) oral antipsychotic patients. AOM 400 patients had better medication adherence (adjusted mean PDC: 57.0% vs. 47.6%, p<0.001) than the oral cohort. Sixty-three percent of AOM 400 patients were partially (PDC 40%-79%) to fully adherent (PDC >80%) vs. 51.1% of oral antipsychotic patients (p<0.001). AOM 400 patients also had a lower medication discontinuation rate (75.2% vs. 85.0%; p<0.001) within 1 year. Median time to discontinuation of AOM 400 was 193 days vs. 89 days for oral antipsychotics (p<0.001). In the Cox model, oral antipsychotic patients discontinued their index treatment at a higher rate than AOM 400 patients (hazard ratio: 1.45; p<0.001). Discussion: This real-world study suggests that patients with schizophrenia initiating AOM 400 had better medication adherence and lower discontinuation risk than patients who changed to different oral antipsychotics. Background: Childhood trauma has been proposed as a risk factor for schizophrenia. Moreover, it has been related to brain abnormalities associated with cognitive functions, including social cognition. Alterations in mentalizing skills are found in both schizophrenia patients and individuals exposed to childhood trauma. We hypothesize that childhood trauma might be related to emotional processing deficits in psychotic patients.
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Methods:
The present study is ongoing. To date, we have assessed social cognition and childhood trauma in 30 patients with schizophrenia. Social cognition is quantified using Mayer, Salovey and Caruso emotional intelligence test (MSCEIT) with five different categories: i) emotional perception, ii) emotional facilitation, iii) emotional comprehension, iii) emotional management and iv) emotional intellectual quotient dimensions. Early trauma data is collected using Childhood Trauma Questionnaire (CTQ), which yields physical, emotional, sexual abuse and neglect scores. We have assessed the correlation coefficients (Spearman´s rho) between childhood trauma and social cognition scores. Results: According to our preliminary analyses, there are significant inverse correlation coefficients in the patients group between emotional neglect and total trauma scores and, on the other hand, social cognition scores for the facilitation, comprehension, management and emotional intellectual quotient dimensions. Thus, patients with higher scores reflecting more severe emotional neglect and total trauma performed lower in social cognition tests. Background: Deficits in social cognition often develop during the prodromal stages of psychosis, remain stable over the course of the illness, and have a dramatic impact on daily functioning (Fett et al., 2011) . Social cue processing, particularly face perception, plays a critical role in social cognitive functioning. Patients with schizophrenia struggle to extract information from faces and interpret facial expressions (Kohler et al., 2010) . These deficits may be explained by restricted visual attention. Indeed, eye-tracking studies have demonstrated that people with schizophrenia show reduced exploratory behaviour (i.e. reduced number of fixations and longer fixation durations) in response to facial stimuli compared to healthy controls (e.g. Manor et al., 1999) . Oxytocin has been demonstrated to exert pro-social effects on behaviour and modulate eye gaze during perception of faces. In the present study, we tested whether the neuropeptide, oxytocin, has a compensatory effect on visual processing of human faces. Methods: Twenty right-handed male subjects with schizophrenia (n = 16) or schizoaffective disorder (n = 4) were administered intranasal oxytocin 40UI or placebo in a double-blind, placebo-controlled, crossover fashion during two visits separated by 7 days. Participants engaged in a free-viewing eye-tracking task, during which they were looking at 6 facial images of two Caucasian men displaying angry, happy, and neutral facial expressions, and 6 control images in a random order. Eyetracking measures including 1) total number of fixations, 2) dispersion, 3) saccade amplitude, and 4) mean duration of fixations were captured using the EyeLink 1000 system (SR Research Ltd, Ottawa, Ontario, Canada). Four separate 2 x 4 repeated-measures analysis of variance (ANOVA) were carried out to evaluate the within-subject effects of treatment, stimuli, and the interactions between stimuli and treatment (p < .05, two-tailed). Results: We found a main effect of treatment (F1,17 = 16.139, p = .001), but not a main effect of stimuli (F3,51 = 1.479, p > .231) on total number of fixations. There was a main effect of treatment on duration of fixation, (F1,13 = 5.455, p = .036) but not a main effect of stimuli (F3,39 = 1.267, p = .299). For dispersion, there was a significant main effect of stimuli (F3,51 = 3.424, p = .024) but no main effect of treatment (F1,17 = 3.170, p = .093). Analysis of saccade amplitudes revealed no main effect of treatment (F1,17 = 2.666, p = .121) or stimuli (F3,51 = 0.289, p = .833). None of the interactions reached significance. Discussion: To our knowledge, this is the first study to explore the effects of oxytocin on eye movements in individuals with schizophrenia. We found that oxytocin increased exploratory viewing behaviour in response to affective facial stimuli by significantly increasing the total number and duration of fixations compared to placebo. While previous findings regarding oxytocin have been inconsistent, our findings are in line with research showing that the intranasal administration of 40UI oxytocin may improve social cognitive deficits in schizophrenia (e.g. Davis et al., 2013) . Future experiments may wish to explore the correlation between eye movement changes induced by oxytocin and facial affect recognition in larger samples.
